Stemline Therapeutics, Inc.
(NASDAQ : STML)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 2.30%353.600.0%$6728.26m
BNTXBioNTech SE 5.04%328.350.0%$1093.01m
SNSSSunesis Pharmaceuticals, Inc. -2.32%10.520.7%$735.39m
NVAXNovavax, Inc. -2.54%179.3379.8%$649.04m
AMGNAmgen, Inc. -0.38%241.541.3%$499.24m
BIIBBiogen, Inc. -0.74%326.731.7%$431.26m
VRTXVertex Pharmaceuticals, Inc. 0.60%201.581.9%$414.73m
GILDGilead Sciences, Inc. -2.21%68.291.0%$401.30m
REGNRegeneron Pharmaceuticals, Inc. -1.46%574.612.7%$353.89m
ILMNIllumina, Inc. 0.84%495.753.5%$264.01m
NTLAIntellia Therapeutics, Inc. 3.53%141.852.3%$263.90m
CRSPCRISPR Therapeutics AG 1.70%121.020.6%$144.72m
EXASEXACT Sciences Corp. -3.64%107.8418.1%$123.59m
SGENSeagen Inc. 4.38%153.395.8%$120.23m
CYTKCytokinetics, Inc. 1.09%29.683.2%$115.29m

Company Profile

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. Stemline’s lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial. Behind its lead, Stemline is developing a broad portfolio of compounds directed at this and other high value cancer stem cell targets of a variety of hematological and solid cancers. In addition, Stemline has built a robust discovery platform called “StemScreen®” which the Company has utilized to identify multiple compounds that target and impair cancer stem cells. Stemline also possesses a comprehensive intellectual property portfolio that includes the earliest filings in the cancer stem cell field covering cancer stem cell-directed therapeutics, diagnostics, and drug screening.